Hello everyone! Today, we're diving into Samsung Bioepis' performance for the first half of the year. According to recent reports, Samsung Bioepis recorded 847.1 billion KRW in revenue during the first half of this year. This marks a 5.7% increase compared to the same period last year, serving as a key indicator of the company's growth trajectory.

First-Half Performance Analysis

Samsung Bioepis' operating profit for the first half reached 230.6 billion KRW, a 5.9% increase year-over-year. This growth is primarily driven by the success of its biosimilar business in the global market. However, to meet the annual revenue target of 1.85 trillion KRW, the company needs to generate approximately 1 trillion KRW in revenue in the second half. With a current achievement rate of only 45.8% towards its goal, expectations are high for its second-half performance.

Q1 vs. Q2 Performance Comparison

The first quarter of this year saw significant growth for Samsung Bioepis. Revenue in Q1 stood at 454.9 billion KRW, with an operating profit of 144 billion KRW. Notably, the company achieved a positive momentum with an operating profit margin of 31.7% in the first quarter. However, Q2 presented challenges, with both revenue and operating profit declining by 2.2% and 3.6%, respectively. This was influenced by changes in the supply schedule for key products and increased investment in research and development.

New Product Launches and Future Outlook

Samsung Bioepis is strengthening its competitiveness through the expansion of its global sales network and its robust R&D pipeline. In the first half of this year, the company broadened its market presence by initiating sales of its biosimilars for Eylea and Prolia. Furthermore, it presented clinical trial results for 'SB27', a biosimilar of the blockbuster drug Keytruda, demonstrating its equivalence to the original medication.

• Announcement of Phase 1 and Phase 3 clinical trial results for Keytruda biosimilar 'SB27'
• Entry into global Phase 1 clinical trials for the antibody-drug conjugate (ADC) new drug candidate 'SBE303'
• Advancement of the preclinical stage for the second new drug candidate 'SBE313'

Conclusion and Expectations

Despite global market uncertainties, Samsung Bioepis forecasts an annual revenue growth rate of over 10% for this year. The securities industry also holds a positive outlook, projecting Samsung Biologics' annual revenue to reach between 1.85 trillion and 1.87 trillion KRW. Consequently, as expectations rise for the second-half performance, Samsung Bioepis' future endeavors are drawing significant attention.